SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…
The positive safety profile supports dosing of ‘1104 at higher doses in upcoming Phase 2b trial in EoENEW ORLEANS and…
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company…
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related…
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE)…
AFFIRM is a unique event-driven, fixed-duration design intended to reduce the challenges for patient participation Data will be used to…
All three Fanconi Anemia patients treated with briquilimab achieved full donor engraftment and full blood count recoveryBriquilimab was well tolerated…
SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…
- 850 cancer cell lines screened in Broad Institute’s PRISM lab - - Rencofilstat active on 220 cancer cell lines…